Introduction/Background This systematic review aimed to investigate the clinical utility of next-generation sequencing (NGS) in treating high-grade serous ovarian cancer (HGSC) with targeted therapies other than PARP inhibitors.

Methodology A total of 1198 studies were screened, and 6 case reports met the inclusion criteria.

• Download figure
• Open in new tab
• Download powerpoint

Abstract #514 Figure 1

Results The patients were treated with trametinib, crizotinib, alectinib, AKT inhibitor, everolimus-letrozole, or trastuzumab-pertuzumab. A partial response was observed in patients (n=3) treated with trametinib, crizotinib, or trastuzumab-pertuzumab. One patient treated with alectinib had a complete response, while the patients (n=2) treated with AKT inhibitor or everolimus-letrozole had stable disease and progressive disease, respectively.

Conclusion Further research, including basket trials, is needed to confirm the results.

Disclosures The results suggest that NGS may have a role in identifying effective targeted therapies for patients diagnosed with HGSC.